Trials / Terminated
TerminatedNCT01009281
An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease
A 52 Week Open Label Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti IL-17 Monoclonal Antibody) in Patients With Moderate to Severe Crohn's Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and tolerability of AIN457 in patients with moderate to severe Crohn's disease who already participated and completed the core trial CAIN457A2202.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AIN457 |
Timeline
- Start date
- 2009-10-30
- Primary completion
- 2010-08-19
- Completion
- 2010-08-19
- First posted
- 2009-11-06
- Last updated
- 2021-07-12
- Results posted
- 2021-07-12
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01009281. Inclusion in this directory is not an endorsement.